At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 38 enrolled
Drug / intervention
GRF6021 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-Controlled, Double-Blind Pilot Study to Evaluate the Effect of GRF6021 on Intracellular Signaling Cascades in Blood Leukocytes and Postoperative Recovery Following Primary Hip or Knee Arthroplasty
In Brief
A Phase 2 clinical trial evaluating GRF6021 and Placebo for Postoperative Recovery. Completed, enrolled 38 participants across 1 site.
Detailed Summary
This study will evaluate the safety, tolerability and effect of GRF6021 on clinical recovery parameters in participants undergoing primary hip or knee arthroplasty.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostoperative Recovery
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJun 2019
Enrollment StartJul 2019
Primary CompletionJan 2021
Study CompletionMar 2021
TodayJul 2026
First PostedJun 10, 2019
Enrollment StartJul 12, 2019
Primary CompletionJan 23, 2021
Study CompletionMar 4, 2021
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 7.1 years ago
Interventions
GRF6021biological
for IV infusion
Placeboother
for IV infusion